LVTX - Multiplikator P/S Lava Tx

Tandha merek lavatherapeutics.com (LVTX)

The P/S business valuation demonstrates the asset's market value, where the 9.10 level captures the latest figures. The stability of LAVA Therapeutics N.V. (LVTX) is ensured by T-cell immunotherapy and support from pharma behemoths, which protects the research budget. The development of cancer drugs relies on strategic alliances with industry leaders. The current development vector is focused on the expansion of bispecific antibodies against solid tumors, funded by substantial partner advances.

LVTX (LAVA Therapeutics N.V.) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 06.12.2025

LAVA Therapeutics N.V. (LVTX) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Analisis umum perusahaan:Lava Tx, LVTX
Produk asil prodhuksi Lava Tx

Geopolitical fragmentation and logistical disruptions are limiting the scale of LAVA Therapeutics N.V. (LVTX) clinical trials, creating risks for operating revenue. By analyzing the P/S time series, an investor can see the ratio of market capitalization to annual sales volume. This multiple determines the cost of every dollar of revenue, allowing one to separate a speculative bubble from real assets. An excessively low ratio may signal a hidden crisis or an undervalued business.

Perusahaan pesaing

Kapitalisasi marang pendapatan ImmunityBio Corp IBRX|Immunocore Holdings - Kapitalisasi marang pendapatan|Multiplikator P/S Janux Corp JANX|RCUS - Rasio rega marang pendapatan|ZYME (zymeworks.com) - Rasio kapitalisasi marang pendapatan|Tango Therapeutics Corp (TNGX) - Rasio rega marang pendapatan|Rega marang dodolan Iovance (IOVA)|Kapitalisasi marang pendapatan IMTX|XNCR - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan CMPX (Compass Bio)|Kapitalisasi marang volume dodolan REPL|Multiplikator P/S LYEL (Lyell Immunopharma, Inc.)|Rasio kapitalisasi pasar marang pendapatan IPHA|Pyxis - Multiplikator P/S|Rega marang dodolan Compugen|IO Biotech, Inc. (IOBT) - Rasio rega marang pendapatan|Sutro Biopharma, Inc. - Rasio kapitalisasi pasar marang pendapatan|INKT (minktherapeutics.com) - Multiplikator P/S|Multiplikator P/S werewolftx.com|Rasio rega marang pendapatan immixbio.com (IMMX)|ALXO: Rasio rega marang dodolan|Multiplikator P/S CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Rega marang dodolan|SONN - Rasio rega marang pendapatan|MAIA Biotechnology, Inc. (MAIA) - Kapitalisasi marang pendapatan|LIMN: Multiplikator P/S|Rega marang dodolan NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Multiplikator P/S|INTS (Intensity Therapeutics) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan gritstonebio.com GRTS|Rasio kapitalisasi pasar marang pendapatan KA|NEXI - Rasio rega marang pendapatan|Turnstone Biologics Corp. - Kapitalisasi marang volume dodolan|VCNX: Multiplikator P/S|Rasio kapitalisasi marang pendapatan HARP